Pacira Legal Information

Pacira Pharmaceuticals, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira’s affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives (“Agents”), for any information, projections, or any of the opinions contained herein, or for any errors, omissions or misstatements. Neither Pacira nor any of Pacira’s affiliates, nor any of their respective Agents makes or has authorized to be made any representations or warranties (express or implied) in relation to Pacira or this website or as to the truth, accuracy or completeness of the information contained on this website, or any other written or oral statement provided in connection herewith, (the “Data”).

Neither the issue of the Data nor any part of its contents constitutes an offer to sell or invitation to purchase any of the products or services or assets described herein or any of the same relating thereto (the “Products”), and no information set out in the Data or referred to in any other written or oral information provided in connection with the Products is intended to form the basis of any decision to enter into any agreement or transaction with respect to the Products. Neither the issue of the Data nor any part of its contents is to be taken as any form of commitment on the part of Pacira or any of Pacira’s affiliates, nor any of their respective Agents to proceed with any agreement or transaction with respect to the Products.

Neither Pacira nor any of Pacira’s affiliates, nor any of their respective Agents undertakes any obligation to provide you or any other party with access to any additional information or to update or correct any inaccuracies in or omissions with respect to the Data, and the right is reserved, without giving reason, at any stage and in any respect to amend any content or proposed timetable, and to terminate any procedure or discussions or negotiations with you or any prospective purchaser In no circumstances will Pacira nor any of Pacira’s affiliates, nor any of their respective Agents be responsible for any costs or expenses incurred in connection with any appraisal or investigation of the Products or the viewing or use of the Data, or for any other costs and expenses incurred by you or any prospective purchasers in connection with any agreement or transaction related thereto. The Data should not be considered as a recommendation by Pacira, nor any of Pacira’s affiliates, nor any of their respective Agents to enter into any agreement or transaction related to the Products or for the viewing or use of the Data. You are recommended to seek your own scientific, clinical, medical, financial and other advice as you, in your sole discretion, deem necessary and appropriate and should rely solely on your own judgment, review and analysis in evaluating the Data and Products.

Important Notice

This site is for informational purposes only and is intended to address medical questions from healthcare professionals in the United States.

To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-RX-EXPAREL (1-855-793-9727).

These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.

Important Safety Information

Warnings and Precautions Specific to EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products

Please refer to full Prescribing Information.

Important Safety Information

Medical Information

US healthcare professionals Click Here

Non-US healthcare professionals can submit a request to medinfo@pacira.com

If you are not a healthcare professional, please discuss any questions you have regarding your health or treatment with your physician, pharmacist, nurse, or other healthcare professional.

Important information about EXPAREL®

The FDA confirms that EXPAREL has always been approved for "administration into the surgical site to produce postsurgical analgesia" for use in a variety of surgeries not limited to those studied in its pivotal trials.

"We are pleased to announce a successful collaboration with the FDA to resolve this matter in an expeditious and meaningful way that allows us to get back to the important task at hand—reducing postsurgical opioid exposure by providing a non-opioid option like EXPAREL to as many patients as appropriate."

- Dave Stack, Chief Executive Officer and Chairman of Pacira

The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.

Important Safety Information

  • EXPAREL is contraindicated in obstetrical paracervical block anesthesia
  • In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting
  • EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients
  • Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations

Warnings and Precautions Specific to EXPAREL

  • EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks, or intravascular or intra-articular use
  • Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products

  • Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesias. CNS reactions are characterized by excitation and/or depression
  • Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias sometimes leading to death
  • Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients
  • Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use

Please refer to full Prescribing Information.

PATIENTS

Click Here >

to continue to the Patient site.

DOCTORS

Click Here >

to continue to the HCP site.

EXPAREL® (bupivacaine liposome injectable suspension) Sign Up

Sign up to receive updates on EXPAREL.

 
Providing the optional information about you below enables us to provide information geared to your needs.
Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy
 

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.